May 17 2005
GSK Confirms Proposed Changes Will Not Impact Supply of Current GSK Medicines in New Zealand Or Ongoing Clinical Trials
GSK Pharmaceuticals New Zealand has decided to change the way its business is structured in New Zealand. These proposed
changes are the result of an in-depth analysis of the business environment in New Zealand.
GSK Pharmaceuticals is committed to retaining a presence in New Zealand and to working constructively with government
and healthcare professionals in order to help meet the twin challenges of developing alternative models which can
increase access to important medicines, while recognising the need for cost containment.
We are currently talking through the proposed changes with our team and we should be in a position to provide you with
more details at the end of May, once formal consultation has been completed.
GSK Pharmaceuticals can confirm that these proposed changes will not impact the supply of current GSK medicines in New
Zealand.
GSK invests approximately $6.7 million per year in New Zealand on the research and development of new medicines. GSK
does have on-going clinical trials in NZ and these will not be affected by these changes.
As you will appreciate, we are working through a difficult period with our team at the moment. As a result, this is our
focus at the present time and we are unable to comment further.
These changes do not affect GSK Consumer (New Zealand).
ENDS